Acadia Pharmaceuticals | ACAD - Operating Profit


Acadia Pharmaceuticals reported $37.84M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 9.78B 792M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
J&J USD 7.48B 860M Jun/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Prothena USD 25.79M 53M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026